Can hydroxychloroquine cause thrombocytopenia?

Can Hydroxychloroquine Cause Thrombocytopenia?

Yes, hydroxychloroquine can cause thrombocytopenia as a recognized hematologic toxicity, though it is uncommon. The FDA drug label explicitly lists thrombocytopenia as part of the myelosuppression spectrum that can occur with hydroxychloroquine use 1.

Mechanism and Clinical Evidence

Hydroxychloroquine may cause myelosuppression including aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia 1. The FDA label specifically warns about this hematologic toxicity and recommends monitoring blood cell counts periodically in patients on prolonged therapy. If myelosuppression develops that cannot be attributed to the underlying disease, the drug should be discontinued 1.

Case reports confirm this association: Multiple documented cases demonstrate hydroxychloroquine-induced thrombocytopenia in real-world settings. One case described severe thrombocytopenia following open heart surgery in a patient taking hydroxychloroquine 2. Another case documented relapsed thrombocytopenia in a systemic lupus erythematosus patient, where the diagnosis was confirmed by recurrence after re-exposure to the drug 3.

Monitoring Requirements

The 2022 American College of Rheumatology guidelines recommend:

• CBC monitoring annually for patients on hydroxychloroquine 4
• This is less frequent than some other DMARDs but reflects the generally favorable safety profile

However, the FDA label advises more vigilant monitoring:

• Periodic blood cell counts in patients on prolonged therapy 1
• If thrombocytopenia develops and cannot be attributed to the underlying disease, discontinue hydroxychloroquine immediately

Clinical Context and Differential Diagnosis

Important caveats when evaluating thrombocytopenia in hydroxychloroquine users:

The diagnosis of drug-induced thrombocytopenia relies primarily on:

• Exclusion of other causes
• Temporal correlation with drug use
• Resolution after discontinuation
• Recurrence upon re-challenge (when documented) 2

Tests for drug-dependent antibodies are time-consuming and not commonly available, so clinical judgment based on discontinuation and correlation is the standard approach 2.

In patients with connective tissue diseases (the primary users of hydroxychloroquine), thrombocytopenia may be disease-related rather than drug-induced. For example, immune thrombocytopenia is a recognized complication of SLE and primary Sjögren's syndrome 5. Interestingly, hydroxychloroquine may actually improve thrombocytopenia in some pSS patients, with one study showing benefit (OR = 1.81) 6.

Risk Assessment

While thrombocytopenia from hydroxychloroquine is uncommon, it can be severe and potentially life-threatening 2. The clinical course is usually mild, but some patients may experience serious hemorrhagic complications 2.

The decision to discontinue hydroxychloroquine depends on:

• Severity of thrombocytopenia
• Clinical bleeding manifestations
• Whether the low platelet count can be attributed to the underlying disease
• Overall clinical condition of the patient 2

Practical Approach

When thrombocytopenia develops in a patient taking hydroxychloroquine:

1. Review the complete medication history - multiple drugs can cause thrombocytopenia 2
2. Assess whether the underlying disease could explain the finding - particularly in SLE or pSS patients 5
3. Check baseline and serial CBC values to establish temporal relationship
4. If drug-induced thrombocytopenia is suspected and clinically significant, discontinue hydroxychloroquine 1
5. Monitor platelet recovery after discontinuation to confirm the association

The medication history must be carefully reviewed in all patients presenting with thrombocytopenia, and any potentially causative medications should be discontinued 2.